ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2370

The Effectiveness Of Biological Agents Concomitant With Tacrolimus In Rheumatoid Arthritis

Kenya Terabe1, Toshihisa Kojima2, Nobunori Takahashi1, Koji Funahashi3, Atsushi Kaneko4, Daihei Kida5, Yuichiro Yabe6, Yuji Hirano7, Masatoshi Hayashi8 and Naoki Ishiguro1, 1Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya, Japan, 3Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 4Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 5Department of Rheumatology and Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 6Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan, 7Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 8Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biologic agents, rheumatoid arthritis, treatment and tacrolimus

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose:In Japan, oral tacrolimus (TAC) was approved for the treatment of RA in 2005 and the improvement of symptoms thorough the use concomitant with disease modifying antirheumatic drugs (DMARDs), including MTX has been reported. On the other hand, the efficacy and tolerance of biological agents therapy concomitant with TAC are unknown. The objective of this study was to investigate the efficacy and tolerance of biological agents concomitant with TAC in Japanese patients with RA using retention rate analysis.

Methods: Total patients (n=1541) who underwent 4 biological agents (etanercept: ETN, adalimumab: ADA, tocilizumab: TCZ, abatacept: ABT) treatment between 2003 and 2011 at Nagoya University Hospital and 12 other institutes (Tsurumai Biologics Communication Study Group) were enrolled. In each biologics analysis, patients were divided into three groups: (1) concomitant only MTX (MTX group) (2) concomitant only TAC (TAC group) (3) monotherary (mono group). In TAC or MTX group, these drugs were only ones which concomitant with biologics. Patients who underwent biologics combined with other DMARDs were excluded. Kaplan-Meier analysis was used to estimate retention rate in each biologics group. To estimate the tolerance of concomitant biologics with TAC, cumulative hazard function was performed in each biologics group.

Results: In total 1541 patients, 91 patients (5.9%) administered each biologics concomitant with TAC (ETN: n=38, 101.0 patient-years (PY) ADA: n=13, 12.8 PY TCZ: n=24, 40.8 PY ABT: n=17, 16.2 PY). Average dosages of TAC at starting were ETN: 2.1±0.7mg ADA: 1.5±1.0mg TCZ: 2.2±0.9mg ABT: 2.4±0.9mg. With comparison of retention rate in each biologics concomitant with TAC, ADA was significantly lower rate than other 3 biologics (fig1). Each biologics agent’s number was ETN (MTX: n=641, 1473.0 PY mono: n=194, 469.1PY), ADA (MTX: n=641, 1473.0 PY mono: n=34, 35.2PY), TCZ (MTX: n=181, 247.5 PY mono: n=85, 120.0PY), ABT (MTX: n=85, 89.6 PY mono: n=38, 35.1PY). In only ETN analysis, the retention rate of TAC group was higher than mono group (fig2). In ADA, that of MTX group was higher than TAC and mono group. There was no difference of comparison that of other 2 biologics analysis. Comparison of incidence of adverse event between TAC and mono group using cumulative hazard function in each biologics analysis, in only ETN analysis incident rate of mono group was higher than TAC group and there was no difference in other 3 biologics analysis.

Conclusion: We suspected that combination therapy ETN and TAC are subsequent options for treatment to RA patient, especially in whom MTX cannot be administration.


Disclosure:

K. Terabe,
None;

T. Kojima,
None;

N. Takahashi,
None;

K. Funahashi,
None;

A. Kaneko,
None;

D. Kida,
None;

Y. Yabe,
None;

Y. Hirano,
None;

M. Hayashi,
None;

N. Ishiguro,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken and Pfizer,

2,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken, Pfizer, Taisho-Toyama and Otsuka,

8.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effectiveness-of-biological-agents-concomitant-with-tacrolimus-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies